Elevance Health, Inc. ELV
We take great care to ensure that the data presented and summarized in this overview for Elevance Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELV
View all-
Vanguard Group Inc Valley Forge, PA21.3MShares$8.41 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY20.7MShares$8.15 Billion0.26% of portfolio
-
State Street Corp Boston, MA10.7MShares$4.21 Billion0.23% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.2MShares$4 Billion0.61% of portfolio
-
Geode Capital Management, LLC Boston, MA4.85MShares$1.91 Billion0.21% of portfolio
-
Sanders Capital, LLC West Palm Beach, FL4.61MShares$1.81 Billion3.48% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$1.76 Billion0.42% of portfolio
-
Capital International Investors Los Angeles, CA3.85MShares$1.51 Billion0.4% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.79MShares$1.49 Billion0.52% of portfolio
-
Morgan Stanley New York, NY3.45MShares$1.36 Billion0.13% of portfolio
Latest Institutional Activity in ELV
Top Purchases
Top Sells
About ELV
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Insider Transactions at ELV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Grant, award, or other acquisition
|
Direct |
3,799
+15.3%
|
-
|
Nov 01
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Payment of exercise price or tax liability
|
Direct |
1,649
-8.73%
|
$682,686
$414.01 P/Share
|
Nov 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+15.55%
|
-
|
Nov 01
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
846
-10.04%
|
$350,244
$414.01 P/Share
|
Oct 18
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
7,417
-46.82%
|
$3,204,144
$432.14 P/Share
|
Oct 02
2024
|
Mark Kaye EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,818
-12.24%
|
$1,423,090
$505.16 P/Share
|
Aug 05
2024
|
Ramiro G Peru Director |
SELL
Open market or private sale
|
Direct |
753
-7.93%
|
$399,843
$531.52 P/Share
|
Jul 22
2024
|
Gail Boudreaux President and CEO |
SELL
Open market or private sale
|
Direct |
34,000
-3.78%
|
$17,034,000
$501.74 P/Share
|
Jul 19
2024
|
Robert L Dixon Jr Director |
SELL
Open market or private sale
|
Direct |
305
-3.04%
|
$154,330
$506.76 P/Share
|
May 15
2024
|
Ramiro G Peru Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.93%
|
-
|
May 15
2024
|
Ryan M. Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+6.07%
|
-
|
May 15
2024
|
Deanna D Strable Soethout Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+27.08%
|
-
|
May 15
2024
|
Elizabeth E Tallett Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.63%
|
-
|
May 15
2024
|
Susan D. De Vore Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+18.57%
|
-
|
May 15
2024
|
Robert L Dixon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.73%
|
-
|
May 15
2024
|
Lewis Hay Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.44%
|
-
|
May 15
2024
|
Bahija Jallal Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+8.48%
|
-
|
May 15
2024
|
Antonio F Neri Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+8.23%
|
-
|
May 15
2024
|
R Kerry Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+4.12%
|
-
|
Apr 24
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Open market or private sale
|
Direct |
6,199
-9.71%
|
$3,297,868
$532.41 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 95.4K shares |
---|---|
Exercise of conversion of derivative security | 28K shares |
Payment of exercise price or tax liability | 39.8K shares |
---|---|
Open market or private sale | 94.5K shares |